Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Forest Healthcare, a wholly owned subsidiary of Forest Laboratories, and Gruenenthal GmbH have entered into an agreement whereby Forest has acquired all rights currently held by Gruenenthal for Colistin and all rights previously licensed by Forest to Gruenenthal for Colobreathe.
Subscribe to our email newsletter
Colistin is an antibiotic used to treat the principal bacterial infections in cystic fibrosis (CF) patients, and Colobreathe is a novel dry powder inhaler containing Colistin developed by Forest and currently being reviewed by the European Medicines Agency.
Forest holds market authorizations for and markets Colistin in the UK and Ireland, while Gruenenthal holds market authorizations for and markets Colistin in several other European markets.
With this transaction, Forest will expand its European cystic fibrosis franchise and become a major distributor of colistin in Europe.
Gruenenthal Group CEO Harald Stock said the divestiture is the next logical step in implementing their strategy to focus on development and marketing of innovative pain medication.
"With Forest we have found an attractive buyer for the CF business and we are convinced that Forest will open new and promising perspectives for CF patients," Stock said.
Forest chairman and CEO Howard Solomon said acquiring Colistin from Gruenenthal is a strategic fit for Forest because it is a first step to expand the commercial capabilities in Europe in addition to their existing presence in the UK and Ireland.